Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diels

Showing results (331-340 of 351) with videos related to

Pageof 36
Sort By:
Molecular Cancer Therapeutics|September 6, 2014
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platformWim Dokter, Ruud Ubink, Miranda van der Lee, et al.
Microorganisms|March 29, 2023
Identification of Z-Tyr-Ala-CHN<sub>2</sub>, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2Jordi Doijen, Koen Temmerman, Christel Van den Eynde, et al.
Facial Plastic Surgery & Aesthetic Medicine|August 28, 2025
International, Multispecialty Expert Consensus on Nomenclature for Facial ParalysisSamuel L Oyer, Rachel Baptista, Kofi Boahene, et al.
Nature Communications|June 11, 2020
A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes regionJean Claude Semuto Ngabonziza, Chloé Loiseau, Michael Marceau, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Molecular Cancer Therapeutics|January 16, 2015
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast CancersMiranda M C van der Lee, Patrick G Groothuis, Ruud Ubink, et al.
Molecular Pharmaceutics|January 31, 2015
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985Ronald C Elgersma, Ruud G E Coumans, Tijl Huijbregts, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Physiologia Plantarum|September 16, 2024
An Improved Chromosome-scale Genome Assembly and Population Genetics resource for Populus tremulaKathryn M Robinson, Bastian Schiffthaler, Hui Liu, et al.
Pageof 36

Showing results (331-340 of 351) with videos related to

Sort By:
Pageof 36
Molecular Cancer Therapeutics|September 6, 2014
Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platformWim Dokter, Ruud Ubink, Miranda van der Lee, et al.
Microorganisms|March 29, 2023
Identification of Z-Tyr-Ala-CHN<sub>2</sub>, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2Jordi Doijen, Koen Temmerman, Christel Van den Eynde, et al.
Facial Plastic Surgery & Aesthetic Medicine|August 28, 2025
International, Multispecialty Expert Consensus on Nomenclature for Facial ParalysisSamuel L Oyer, Rachel Baptista, Kofi Boahene, et al.
Nature Communications|June 11, 2020
A sister lineage of the Mycobacterium tuberculosis complex discovered in the African Great Lakes regionJean Claude Semuto Ngabonziza, Chloé Loiseau, Michael Marceau, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
Molecular Cancer Therapeutics|January 16, 2015
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast CancersMiranda M C van der Lee, Patrick G Groothuis, Ruud Ubink, et al.
Molecular Pharmaceutics|January 31, 2015
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985Ronald C Elgersma, Ruud G E Coumans, Tijl Huijbregts, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Physiologia Plantarum|September 16, 2024
An Improved Chromosome-scale Genome Assembly and Population Genetics resource for Populus tremulaKathryn M Robinson, Bastian Schiffthaler, Hui Liu, et al.
Pageof 36